Compare
Nano-X Imaging Ltd. vs Escalon Medical Corp vs CapsoVision, Inc vs Hyperfine, Inc.
| Latest fiscal year | Nano-X Imaging Ltd. NNOX | Escalon Medical Corp ESMC | CapsoVision, Inc CV | Hyperfine, Inc. HYPR |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2026-06-30 | 2025-12-31 | 2025-12-31 |
| Revenue | $13.02M | $12.74M | $13.55M | $13.56M |
| Revenue growth (YoY) | +15.4% | +5.7% | +15.3% | +5.2% |
| Gross margin | -98.2% | 43.7% (computed) | 52.9% | 49.8% |
| Operating margin | -600.8% | 0.4% | -188.3% | -273.4% |
| Net margin | -576.1% | 31.5% | -186.8% | -262.3% |
| Net income | -$75.02M | $4.01M | -$25.32M | -$35.57M |
| EPS (Diluted) | -$1.16 | $0.27 | -$1.03 | -$0.43 |
| Operating cash flow | -$40.79M | -$402.6K | -$22.86M | -$27.95M |
| Free cash flow | -$45.00M | -$407.0K | -$22.95M | -$29.13M |
| Cash & equivalents | $49.15M | $3.07M | n/a | $35.09M |
| Total assets | $162.16M | $9.13M | $18.16M | $55.26M |
| Total liabilities | $22.43M | $3.20M | $4.90M | $14.26M |
| Shareholders' equity | $139.73M | $5.93M | $13.26M | $41.01M |
| Return on year-end equity | -53.7% | 67.7% | -190.9% | -86.8% |
| Shares outstanding | n/a | 7.42M | 46.87M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Nano-X Imaging Ltd. | Escalon Medical Corp | CapsoVision, Inc | Hyperfine, Inc. |
|---|---|---|---|---|
| Latest | $13.02M Ended 2025-12-31 | $12.74M Ended 2026-06-30 | $13.55M Ended 2025-12-31 | $13.56M Ended 2025-12-31 |
| 1 year earlier | $11.28M Ended 2024-12-31 | $12.05M Ended 2025-06-30 | $11.76M Ended 2024-12-31 | $12.89M Ended 2024-12-31 |
| 2 years earlier | $9.90M Ended 2023-12-31 | $11.98M Ended 2024-06-30 | n/a | $11.03M Ended 2023-12-31 |
| 3 years earlier | $8.58M Ended 2022-12-31 | $12.18M Ended 2023-06-30 | n/a | $6.81M Ended 2022-12-31 |
| 4 years earlier | $1.30M Ended 2021-12-31 | $10.70M Ended 2022-06-30 | n/a | $1.50M Ended 2021-12-31 |